Virobay, Inc. is a biotechnology company specializing in small molecule drug discovery and development, focusing on cysteine protease inhibitors to treat conditions like neuropathic pain, autoimmune diseases, fibrosis, liver diseases, and initially hepatitis C. [1][2][3][4] Headquartered in Menlo Park, California, and founded in 2006, it leverages a proprietary cathepsin platform spun out from Celera Genomics to advance clinical candidates, though many programs like VBY-129, VBY-825, VBY-376, VBY-891, and VBY-036 have been discontinued.[1][4] The company serves patients with unmet needs in these therapeutic areas, solving problems through targeted enzyme inhibition, with past growth evidenced by an $8 million Series B financing in 2014 to fund clinical advancement, particularly VBY-036 for neuropathic pain, and reported revenue of $9.9 million.[3][4]
Virobay was established in 2006 by Robert F. G. Booth, who serves as President and CEO, with its foundational cathepsin platform and management team spun out from Celera Genomics, a former leader in cathepsin research.[1][4] The idea emerged from expertise in protease inhibitors, initially targeting anti-viral treatments like hepatitis C via protease and polymerase inhibitors, before evolving to broader applications in neuropathic pain, autoimmune disorders, dermatology, and fibrosis.[2][4] Early traction included building a clinical pipeline and securing investments; by 2014, it completed an $8 million Series B led by investors like Perceptive Advisors, with support from existing backers, to propel programs forward.[4] Key figures include David Karpf as VP and Chief Medical Officer.[3]
Virobay rides the wave of precision medicine in biotech, particularly enzyme-targeted therapies for fibrosis, autoimmune diseases, and neuropathic pain, amid growing demand for novel small molecule drugs in areas underserved by existing treatments.[1][3][4] Timing aligns with advances in protease inhibitor tech post-Celera spin-out, capitalizing on market forces like rising chronic disease prevalence (e.g., liver fibrosis, neuralgia) and biotech investment surges in the 2010s, evidenced by its Series B and VC ties.[4][5] It influences the ecosystem by contributing to cathepsin research, competing with giants like Amgen, Gilead, and Vertex, and demonstrating spin-out models that transfer big-pharma IP to agile biotechs.[3] However, discontinued pipelines highlight risks in clinical translation, underscoring broader biotech challenges in advancing candidates to market.[1]
Virobay's legacy in cathepsin inhibitors positions it for potential revival in fibrosis or pain therapies, especially if restarted programs leverage its platform amid ongoing biotech M&A trends. Emerging trends like AI-driven drug design and combo therapies for autoimmune/liver diseases could reshape its path, with its VC network enabling partnerships or acquisitions. Influence may evolve through licensing tech or team expertise, tying back to its roots as a Celera spin-out pioneering protease innovation in a high-stakes biotech arena.[1][4][5]
Virobay has raised $18.0M in total across 2 funding rounds.
Virobay's investors include Alta Partners.
Virobay has raised $18.0M across 2 funding rounds. Most recently, it raised $8.0M Series B in July 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2014 | $8.0M Series B | Alta Partners | |
| Jun 1, 2010 | $10.0M Venture Round | Alta Partners |
